Schizophrenia is a severe mental illness affecting approximately 1% of the population worldwide. Antipsychotic drugs are effective in symptom control in up to two-thirds of patients, but in at least one-third of patients the response is poor. The reason for this is not clear, but one possibility is that good and poor responders have different neurochemical pathologies, and may therefore benefit from different treatment approaches. In this selective review we summarise research findings investigating the biological differences between patients with schizophrenia who show a good or a poor response to treatment with antipsychotic drugs.
Abi-Dargham A., Moore H. ( 2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist9: 404-416.
2.
Abi-Dargham A., Rodenhiser J., Printz D., et al. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A97: 8104-8109.
3.
Adams DH, Close S., Farmen M., Downing AM, Breier A. and Houston JP ( 2008) Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder . Hum Psychopharmacol23(4): 267-274.
4.
Addington D., Addington J. ( 1990) Depression dexamethasone nonsuppression and negative symptoms in schizophrenia. Can J Psychiatry35: 430-433.
5.
Agid O., Mamo D., Ginovart N., Vitcu I., Wilson AA, Zipursky RB, Kapur S. ( 2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology32: 1209-1215.
6.
Alenius M., Wadelius M., Dahl ML, Hartvig P., Lindstrom L. and Hammarlund-Udenaes M. ( 2008) Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res42(11): 884-893.
7.
Alfredsson G., Wiesel FA ( 1990) Relationships between clinical effects and monoamine metabolites and amino acids in sulpiridetreated schizophrenic patients. Psychopharmacology (Berl) 101: 324-331.
8.
Allan CL, Cardno AG, McGuffin P. ( 2008) Schizophrenia: from genes to phenes to disease. Curr Psychiatry Rep10: 339-343.
9.
Amin F., Davidson M., Kahn RS, et al. (1995) Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull21: 53-66.
10.
Arango C., Breier A., McMahon R., Carpenter WT, Jr, Buchanan RW ( 2003) The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry160: 1421-1427.
11.
Arranz M., Collier D., Sodhi M., et al. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet346(8970): 281-282.
12.
Arranz MJ, Bolonna AA, Munro J., Curtis CJ, Collier DA, Kerwin RW ( 2000a) The serotonin transporter and clozapine response. Mol Psychiatry5: 124-125.
13.
Arranz MJ, Collier DA, Munro J., et al. (1996) Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett217: 177-178.
14.
Arranz MJ, de Leon J. ( 2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry12: 707-747.
15.
Arranz MJ, Li T., Munro J., et al. (1998) Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response . Pharmacogenetics8(6): 481-484.
16.
Arranz MJ, Munro J., Osborne S., Collier D., Kerwin RW ( 2000b) Difficulties in replication of results. Lancet356(9238): 1359-1360.
17.
Banki CM, Arato M., Rihmer Z. ( 1984) Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test. Neuropsychobiology11: 174-177.
18.
Barlas IO, Cetin M., Erdal ME, et al. (2009) Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet150B(1): 56-60.
19.
Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI ( 2003) Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry11: 648-657.
20.
Bertolino A., Caforio G., Blasi G., et al. (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry161(10): 1798-1805.
21.
Bertolino A., Caforio G., Blasi G., et al. (2007) COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res95: 253-255.
22.
Birkett JT, Arranz MJ, Munro J., Osbourn S., Kerwin RW, Collier DA ( 2000) Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport11: 2017-20.
23.
Bishop JR, Ellingrod VL, Moline J., Miller D. ( 2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res77: 253-260.
24.
Bolonna AA, Arranz MJ, Munro J., et al. (2000) No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett280: 65-68.
25.
Bowers MB, Jr, Swigar ME, Jatlow PI, Goicoechea N. ( 1984) Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry45: 248-251.
Brown AS, Gewirtz G., Harkavy-Friedman J., et al. (1997) Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology17: 317-325.
28.
Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. ( 1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology13: 177-213.
29.
Buchanan RW, Breier A., Kirkpatrick B., Ball P., Carpenter WT, Jr ( 1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry155: 751-760.
30.
Buchsbaum MS, Potkin SG, Siegel BV, Jr, et al. (1992) Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry49(12): 966-974.
31.
Carroll BJ, Feinberg M., Greden JF, et al. (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry38: 15-22.
32.
Catafau AM, Corripio I., Perez V., Martin JC, Schotte A., Carrio I., Alvarez E. ( 2006) Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res148: 175-183.
33.
Ceskova E., Drybcak P., Hrobar P., Lorenc M., Prochazkova H., Spacek J. ( 2001) The changes of biological markers and treatment efficacy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry25: 323-335.
34.
Ceskova E., Drybcak P., Lorenc M. ( 2002) Biological markers and possibilities for predicting therapeutic results in schizophrenia: a methodological contribution. Prog Neuropsychopharmacol Biol Psychiatry26: 683-691.
35.
Chang WH, Chen TY, Lin SK, et al. (1990) Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept. Biol Psychiatry27: 510-518.
36.
Chiu HJ, Wang YC, Liou YJ, Lai IC, Chen JY ( 2003) Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology47(4): 178-181.
37.
Cohen BM, Ennulat DJ, Centorrino F., et al. (1999) Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology ( Berl) 141(1): 6-10.
38.
Coppen A., Abou-Saleh M., Milln P., Metcalfe M., Harwood J., Bailey J. ( 1983) Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry142: 498-504.
39.
Cordeiro Q., Miguita K., Miracca E., Elkis H. and Vallada H. ( 2006) Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia. Sao Paulo Med J124(3): 165-167.
40.
Corripio I., Catafau AM, Perez V., et al. (2005) Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry29: 91-96.
41.
Creese I., Burt DR, Snyder SH ( 1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science192: 481-483.
42.
Crow TJ ( 1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J280(6207): 66-68.
43.
Curtis VA, Wright P., Reveley A., Kerwin R., Lucey JV ( 1995) Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiatry166: 642-646.
44.
Davidson M., Kahn RS, Stern RG, et al. (1993) Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia . Psychiatry Res46(2): 151-163.
45.
Davila R., Manero E., Zumarraga M., Andia I., Schweitzer JW, Friedhoff AJ ( 1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry45(6): 564-567.
46.
Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. ( 2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol24(1): 43-49.
47.
Dewan MJ, Pandurangi AK, Boucher ML, Levy BF, Major LF ( 1982) Abnormal dexamethasone suppression test results in chronic schizophrenic patients. Am J Psychiatry139(11): 1501-1503.
48.
Duncan E., Wolkin A., Angrist B., et al. (1993) Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry34(8): 523-528.
49.
Farde L., Nordstrom AL ( 1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl17): 30-33.
50.
Fathalli F., Rouleau GA, Xiong L., et al. (2008) No association between the DRD3 Ser9Gly polymorphism and schizophrenia. Schizophr Res98(1-3): 98-104.
51.
Friedman L., Lys C., Schulz SC ( 1992) The relationship of structural brain imaging parameters to antipsychotic treatment response: a review. J Psychiatry Neurosci17(2): 42-54.
52.
Garyfallos G., Lavrentiadis G., Amoutzias D., Monas K., Manos N. ( 1993) Negative symptoms of schizophrenia and the dexamethasone suppression test. Acta Psychiatr Scand88(6): 425-428.
53.
Goff DC, Hennen J., Lyoo IK, et al. (2002) Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine . Biol Psychiatry51(6): 493-497.
54.
Green AI, Alam MY, Boshes RA, et al. (1993a) Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res10(1): 33-37.
55.
Green AI, Alam MY, Sobieraj JT, et al. (1993b) Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res46(2): 139-149.
56.
Grunder G., Vernaleken I., Muller MJ, et al. (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology28(4): 787-794.
57.
Gutierrez B., Arranz MJ, Huezo-Diaz P., et al. (2002) Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res58(1): 93-97.
58.
Guzey C., Scordo MG, Spina E., Landsem VM and Spigset O. ( 2007) Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol63(3): 233-241.
59.
Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ ( 2001) Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia . Psychiatr Genet11(4): 219-222.
60.
Hwang R., Shinkai T., De Luca V., et al. (2005) Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology ( Berl) 181(1): 179-187.
61.
Hwang R., Shinkai T., De Luca V., et al. (2007) Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol21(7): 718-727.
62.
Hwu HG, Hong CJ, Lee YL, Lee PC and Lee SF ( 1998) Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry44(6): 483-487.
63.
Illi A., Kampman O., Anttila S., et al. (2003) Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol13(3): 147-151.
64.
Illi A., Kampman O., Hanninen K., et al. (2007) Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum Psychopharmacol22(4): 211- 215.
65.
Inada T., Nakamura A. and Iijima Y. ( 2003) Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet B Neuropsychiatr Genet120B(1): 35-39.
66.
Javaid JI, Sharma RP, Janicak PG, Davis JM ( 1990) Plasma HVA in psychiatric patients: longitudinal studies . Psychopharmacol Bull26(3): 361-365.
67.
Javitt DC ( 2001) Management of negative symptoms of schizophrenia. Curr Psychiatry Rep3(5): 413-417.
68.
Javitt DC ( 2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry19(2): 151-157.
69.
Jones H., Curtis VA, Wright P., Lucey JV ( 1998) Neuroendocrine evidence that clozapine’s serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Am J Psychiatry155(6): 838-840.
70.
Jones H., Curtis VA, Wright P., Pilowsky LS, Lucey JV ( 2002) D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients. Psychiatry Res113(1-2): 41-47.
71.
Kahn RS, Davidson M., Siever L., Gabriel S., Apter S., Davis KL ( 1993) Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry150(9): 1337-1342.
72.
Kaiser R., Konneker M., Henneken M., et al. (2000) Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry5(4): 418-424.
73.
Kaiser R., Tremblay PB, Klufmoller F., Roots I. and Brockmoller J. ( 2002) Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia . Mol Psychiatry7(7): 695-705.
74.
Kane J., Honigfeld G., Singer J., Meltzer H. ( 1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry45(9): 789-796.
75.
Kaneda Y., Kawamura I., Ohmori T. ( 2005) Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia . Clin Neuropharmacol28(6): 262-264.
76.
Kapur S., Remington G. ( 2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry50(11): 873-883.
77.
Kendler KS, Heninger GR, Roth RH ( 1982) Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci30(24): 2063-2069.
78.
Kim B., Choi EY, Kim CY, Song K., Joo YH ( 2008) Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol23(1): 61-67.
79.
Kohn Y., Ebstein RP, Heresco-Levy U., et al. (1997) Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol7(1): 39-43.
80.
Koreen AR, Lieberman J., Alvir J., et al. (1994) Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry51(2): 132-138.
81.
Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH ( 2002) Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry159(9): 1593-1595.
82.
Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH and Chang WH ( 2005) Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol25(1): 6-11.
83.
Lawrie SM, Ingle GT, Santosh CG, et al. (1995) Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia . Br J Psychiatry167(2): 202-210.
84.
Lewis S., Lieberman J. ( 2008) CATIE and CUtLASS: can we handle the truth? Br J Psychiatry192(3): 161-163.
85.
Lieberman JA ( 1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry46(6): 729-739.
86.
Lieberman JA, Kane JM, Safferman AZ, et al. (1994) Predictors of response to clozapine. J Clin Psychiatry55(Suppl B): 126-128.
87.
Lin CH, Tsai SJ, Yu YW, et al. (1999) No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport10(1): 57-60.
88.
Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. ( 1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry168(5): 571-579.
89.
Malhotra AK, Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. ( 1996a) Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry153(8): 1092-1094.
90.
Malhotra AK, Goldman D., Ozaki N., et al. (1996b) Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport7(13): 2100-2102.
91.
Malhotra AK, Goldman D., Buchanan RW, et al. (1998) The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry3(1): 72-75.
92.
Masellis M., Basile V., Meltzer HY, et al. (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology19(2): 123-132.
93.
Masellis M., Basile VS, Meltzer HY, et al. (2001) Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res47(1): 49-58.
94.
Masellis M., Paterson AD, Badri F., et al. (1995) Genetic variation of 5-HT2A receptor and response to clozapine. Lancet346(8982): 1108.
95.
Mauri MC, Vita A., Giobbio GM, et al. (1994) Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol9(1): 3-7.
96.
Mazure CM, Nelson JC, Jatlow PI, Bowers MB ( 1991) Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry30(5): 475-482.
97.
Meltzer HY, Kolakowska T., Fang VS, et al. (1984) Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Arch Gen Psychiatry41(5): 512-519.
98.
Mohr P., Horacek J., Motlova L., Libiger J., Czobor P. ( 1998) Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophr Res30(1): 91-99.
99.
Molero P., Ortuno F., Zalacain M. and Patino-Garcia A. ( 2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J7(6): 418-426.
100.
Molina Rodriguez V., Montz Andree R., Perez Castejon MJ, Capdevila Garcia E., Carreras Delgado JL, Rubia Vila FJ ( 1996) SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry153(10): 1343-1346.
101.
Molina V., Reig S., Pascau J., et al. (2003a) Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Res124(3): 163-175.
102.
Molina V., Reig S., Sarramea F., et al. (2003b) Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res124(3): 153-161.
103.
Molina V., Sanz J., Benito C., Palomo T. ( 2004) Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia. Int Clin Psychopharmacol19(4): 221-228.
104.
Molina V., Tamayo P., Montes C., et al. (2008) Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients . Prog Neuropsychopharmacol Biol Psychiatry32(4): 948-954.
105.
Munro JG, Hardiker TM, Leonard DP ( 1984) The dexamethasone suppression test in residual schizophrenia with depression. Am J Psychiatry141(2): 250-252.
106.
Nagaoka S., Iwamoto N., Arai H. ( 1997) First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry41(8): 857-864.
107.
Neville MJ, Johnstone EC, Walton RT ( 2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat23(6): 540-545.
108.
Nolan KA, Czobor P., Citrome LL, et al. (2006) Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics . J Clin Psychopharmacol26(3): 338-340.
109.
Nothen MM, Rietschel M., Erdmann J., et al. (1995) Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet346(8979): 908-909.
110.
Ohara K., Nagai M., Tani K., Nakamura Y., Ino A. and Ohara K. ( 1998) Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res81(2): 117-123.
111.
Pantelis C., Barnes TR ( 1996) Drug strategies and treatment-resistant schizophrenia . Aust N Z J Psychiatry30(1): 20-37.
112.
Patil ST, Zhang L., Martenyi F., et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med13(9): 1102-1107.
113.
Perkins DO, Gu H., Boteva K., Lieberman JA ( 2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis . Am J Psychiatry162(10): 1785-804.
114.
Petrie EC, Faustman WO, Moses JA, Lombrozo L., Csernansky JG ( 1990) Correlates of rapid neuroleptic response in male patients with schizophrenia. Psychiatry Res33(2): 171-177.
115.
Pickar D., Labarca R., Doran AR, et al. (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry43(7): 669-676.
116.
Pickar D., Labarca R., Linnoila M., et al. (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science225(4665): 954-957.
117.
Pilowsky LS, Bressan RA, Stone JM, et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry11(2): 118-119.
118.
Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW ( 1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet340(8813): 199-202.
119.
Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW ( 1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med23: 791-797.
120.
Potkin SG, Basile VS, Jin Y., et al. (2003) D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry8(1): 109-113.
121.
Pycock CJ, Kerwin RW, Carter CJ ( 1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature286(5768): 74-76.
122.
Rao PA, Pickar D., Gejman PV, Ram A., Gershon ES and Gelernter J. ( 1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry51(11): 912-917.
123.
Reynolds GP, Arranz B., Templeman LA, Fertuzinhos S., San L. ( 2006) Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry163(10): 1826-1829.
124.
Reynolds GP, Yao Z., Zhang X., Sun J. and Zhang Z. ( 2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol15(2): 143-151.
125.
Rietschel M., Naber D., Oberlander H., et al. (1996) Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology15(5): 491-496.
126.
Rietschel M., Naber D., Fimmers R., Moller HJ, Propping P., Nothen MM ( 1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport8(8): 1999-2003.
127.
Savas HA, Unal B., Erbagci H., et al. (2002) Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. Neuropsychobiology46(2): 61-66.
128.
Schafer M., Rujescu D., Giegling I., et al. (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry158(5): 802-804.
129.
Scharfetter J., Chaudhry HR, Hornik K., et al. (1999) Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol10(1): 17-20.
130.
Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS ( 2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology25(4): 468-475.
131.
Schumacher J., Schulze TG, Wienker TF, Rietschel M., Nothen MM ( 2000) Pharmacogenetics of the clozapine response. Lancet356(9228): 506-507.
132.
Schwieler L., Linderholm KR, Nilsson-Todd LK, Erhardt S., Engberg G. ( 2008) Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci83(5-6): 170-175.
133.
Seeman P., Chau-Wong M., Tedesco J., Wong K. ( 1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A72(11): 4376-4380.
134.
Shaikh S., Collier DA, Sham P., et al. (1995) Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet60(6): 541-545.
135.
Shaikh S., Collier DA, Sham PC, et al. (1996) Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet97(6): 714-719.
136.
Sharma RP, Pandey GN, Janicak PG, Peterson J., Comaty JE, Davis JM ( 1988) The effect of diagnosis and age on the DST: a metaanalytic approach. Biol Psychiatry24(5): 555-568.
137.
Shulman Y., Grant S., Seres P., Hanstock C., Baker G., Tibbo P. ( 2006) The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci31(6): 406-410.
138.
Sodhi MS, Arranz MJ, Curtis D., et al. (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport7(1): 169-172.
139.
Stone JM, Davis JM, Leucht S., Pilowsky LS ( 2008a) Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs-An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature. Schizophr Bull.
140.
Stone JM, Erlandsson K., Arstad E., et al. (2008b) Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) 197(3): 401-408.
141.
Stone JM, Morrison PD, Pilowsky LS ( 2007) Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol21(4): 440-452.
142.
Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer HY ( 1997) Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res69(2-3): 113-121.
143.
Suzuki A., Kondo T., Mihara K., et al. (2001) The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients . Pharmacogenetics11(6): 545-550.
144.
Suzuki A., Mihara K., Kondo T., et al. (2000) The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics10(4): 335-341.
145.
Szekeres G., Keri S., Juhasz A., et al. (2004) Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet124B(1): 1-5.
146.
Szulc A., Galinska B., Tarasow E., et al. (2005) The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry38(5): 214-219.
147.
Szymanski S., Lieberman J., Pollack S., et al. (1995) Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. Biol Psychiatry37(1): 52-55.
148.
Tamminga CA, Buchanan RW, Gold JM ( 1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol13(Suppl 3): S21-S26.
149.
Tandon R., Mazzara C., DeQuardo J., et al. (1991) Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry29(10): 953-964.
150.
Tsai SJ, Hong CJ, Yu YW, et al. (2000) Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res44(3): 177-181.
151.
Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ ( 2001) Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response . Schizophr Res49(1-2): 53-58.
152.
Tunbridge EM, Harrison PJ, Weinberger DR ( 2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry60(2): 141-151.
153.
Tuominen HJ, Tiihonen J., Wahlbeck K. ( 2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res72(2-3): 225-234.
154.
van der Heijden FM, Tuinier S., Fekkes D., Sijben AE, Kahn RS, Verhoeven WM ( 2004) Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol14(3): 259-265.
155.
van Kammen DP, Kelley ME, Yao JK, et al. (1996) Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res64(1): 47-58.
156.
Weickert TW, Goldberg TE, Mishara A., et al. (2004) Catechol-Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry56(9): 677-682.
157.
Weinberger DR, Bigelow LB, Kleinman JE, Klein ST, Rosenblatt JE, Wyatt RJ ( 1980) Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment. Arch Gen Psychiatry37(1): 11-13.
158.
Woodward ND, Jayathilake K. and Meltzer HY ( 2007) COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res90(1-3): 86-96.
159.
Wu S., Xing Q., Gao R., et al. (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett376(1): 1-4.
160.
Wu SN, Gao R., Xing QH, et al. (2006) Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin27(8): 966-970.
161.
Xing Q., Qian X., Li H., et al. (2007) The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol10(5): 631-637.
162.
Yazici K., Yazici AE, Taneli B. ( 2002) Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry26(3): 579-584.
163.
Yeragani VK ( 1990) The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry35(2): 128-132.
164.
Yoshimura R., Ueda N., Shinkai K., Nakamura J. ( 2003) Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol18(2): 107-111.
165.
Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ ( 1999) Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport10(6): 1231-1233.
166.
Zai CC, Hwang RW, De Luca V., et al. (2007) Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol10(5): 639-651.
167.
Zalsman G., Frisch A., Lev-Ran S., et al. (2003) DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol13(3): 183-185.
168.
Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD and Chen XG ( 2005) Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci115(11): 1539-1547.
169.
Zipursky RB, Zhang-Wong J., Lambe EK, Bean G., Beiser M. ( 1998) MRI correlates of treatment response in first episode psychosis. Schizophr Res30(1): 81-90.
